As therapies with CXCR2-blocking and microglia-depletion are considered therapeutical (yet still experimental) approaches in glioblastoma therapy, and dexamethasone is a very common symptomatic treatment agent in glioblastoma, we hereby produced meaningful results concerning further studies and clinical evaluations. Here, CXCR2 is linked to glioblastoma.